

Case Report

A case of disseminated melioidosis: clinical insights and management

Satyajit S. Dharme^{1*}, Prasanna H. Gaikwad¹, Preeti N. Jain², Lekharaj V. Kesare¹

¹Department of General Medicine, Bharatratna Dr Babasaheb Ambedkar Municipal and General Hospital, Mumbai, Maharashtra, India

²Department of Pathology, Bharatratna Dr Babasaheb Ambedkar Municipal and General Hospital, Mumbai, Maharashtra, India

Received: 04 January 2026

Revised: 08 May 2026

Accepted: 08 June 2026

*Correspondence:

Dr. Satyajit S. Dharme,

E-mail: sat6180@yahoo.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Melioidosis is an infectious disease of humans and animals resulting from infection with the gram-negative organism *Burkholderia pseudomallei*. Known as the “great mimicker”, melioidosis presents with a wide spectrum of disease including isolated cutaneous/pulmonary disease, primary bacteremia, visceral abscesses or fulminant fatal septicaemia. The mean incubation period is nine days (1-21 days) but symptoms can evolve more quickly (<24 h) following inhalational and/or presumed aspiration events. In acute disease, sepsis syndrome is common; >50% of patients are bacteremic at presentation and 20% develop septic shock. Pulmonary involvement is the most common acute infection in adults responsible for >50% of presentations, while pneumonia is seen in approximately 20% of paediatric cases. Presentations in children more frequently have skin involvement (60%), compared with 13% in adults. In our case report, patient was a 41-year-old male, resident of Ratnagiri district, farmer by occupation, presented with fever for 1 month, cough and breathlessness for same period. He was successfully treated with meropenem and doxycycline and put on maintenance therapy for duration of 12 weeks.

Keywords: Melioidosis, *Burkholderia pseudomallei*, Pneumonia, Sepsis, Fatal, Diabetes mellitus

INTRODUCTION

Melioidosis, also known as Whitmore’s disease, is an infectious disease caused by a bacterium, *Burkholderia pseudomallei* (*B.pseudomallei*, previously known as *Pseudomonas pseudomallei*).¹ Melioidosis, as a disease, has strong associations with climatic conditions and is found in tropical and subtropical regions globally, occurring predominantly in Southeast Asia, Northern Australia, China and Taiwan.^{2,3} South Asia is estimated to have 44% of the global disease burden. Among South Asian countries, Bangladesh and Sri Lanka are considered endemic for melioidosis; a few cases have been reported from Nepal.⁴ India has experienced an increase in numbers of melioidosis cases in the recent years.⁴ The predisposition to melioidosis in those with diabetes,

hazardous alcohol use or chronic renal disease likely reflects impairment of their innate immune function. The disease mainly affects adults (median age-5th decade) with poorly controlled diabetes in the Indian subcontinent-the diabetic capital of the world. Up to 80% of melioidosis cases in India, Sri Lanka and Bangladesh are diabetics.⁴ Additionally, a study on genetic susceptibility to pneumonia during COVID-19 categorized India as having a moderate genetic risk. Taking this into consideration, it could be ascertained that environmental factors and lack of awareness constitute risk factors for melioidosis. Genetic studies related to melioidosis, similar to those in Thailand, could be useful for India.⁵ The signs and symptoms are non-specific and overlap with several diseases, including tuberculosis. Thus melioidosis, ‘the great mimicker’ of many diseases, is grossly underdiagnosed and underreported across the tropics, including India. In South

Asia, where tuberculosis is widely prevalent, any disease like tuberculosis is misdiagnosed, leading to a delay in proper management. The organism is easily mistaken as *Pseudomonas* species in microbiology laboratories and may be dismissed as a common laboratory contaminant. The poor diagnostic sensitivity of blood culture also leads to missed diagnosis. Hence, both clinical ignorance and missed laboratory diagnosis have misrepresented melioidosis as a rare entity.⁴ The clinical presentation is varied and the infection may be acute or chronic, localized or disseminated. It is mainly characterized by formation of abscesses, especially in the lungs, liver, spleen, skeletal muscle and prostate.⁶

Melioidosis is a considerable cause of fatal community-acquired pneumonia and septicemia in endemic regions, with mortality rates as high as 44%. Acute pulmonary infection is the most commonly diagnosed form of melioidosis. Pneumonia may be asymptomatic or may present as a severe necrotizing disease.⁶ Here we discuss a case of 41-year-old male, resident of Ratnagiri district, a known case of type 2 diabetes mellitus who came with complains of fever, breathlessness, cough for one month.

CASE REPORT

A 41-year-old male, resident of Ratnagiri district, a known case of type 2 diabetes mellitus for 12 years on oral anti-diabetic agents, presented with fever of one month duration associated with episodes of chills which was associated with cough with breathlessness for same duration. He also complained of dull aching generalized abdominal pain which started along with fever. It was also associated with generalized weakness with decreased appetite.



Figure 1: Chest radiograph (PA view) showing a right upper lung cavitory lesion with surrounding consolidation, associated bronchiectatic changes and right pleural effusion.

Notably, he had a recent hospitalization for same complaints. Symptoms temporarily receded but relapsed and then patient came to our hospital for further management. On detailed history taking, patient had a past

history of pulmonary tuberculosis 8 years ago, for which he had completed full course of anti-tubercular treatment for 6 months. There was no history of hypertension, bronchial asthma or ischemic heart disease. He had no history of addiction to any substances.




Figure 2: Axial HRCT chest image (lung window) showing a right upper lobe cavitory lesion with surrounding patchy consolidative opacities and associated right pleural effusion.

On examination, the patient was conscious and oriented, with tachycardia (pulse rate 125/min) and blood pressure of 122/92 mm Hg. Random blood glucose was markedly elevated (321 mg/dl) and HbA1C was 10.3 indicating poor glycemic control. Oxygen saturation was 92% on room air and maintained at 98% on oxygen by nasal prongs. On systemic examination revealed right sided crepitations with bronchial breath sounds, normal heart sounds, soft non-tender abdomen and no focal neurological deficits. Laboratory investigations revealed moderate anemia with hemoglobin levels around 8 g/dl, and peripheral smear showed anisocytosis. Total leukocyte count was elevated (15800/cu.mm), with neutrophilia and relative lymphopenia, with normal platelet counts. Inflammatory markers were significantly elevated, with C-reactive protein of 128.1 mg/l and D-dimer of 956 ng/ml, suggesting ongoing systemic inflammation. Renal function tests were within normal limits. Screening for tropical infections, including dengue, leptospirosis, malaria and enteric fever were negative. Sputum studies for Acid Fast Bacilli (AFB) and GeneXpert was negative.

Urine analysis demonstrated glycosuria (3+), proteinuria (2+) and microscopic hematuria (10-15 RBCs per high power field (HPF) and 10-15 pus cell/HPF. Chest radiography revealed homogeneous opacity in the right lower zone with obliteration of the costophrenic angle, consistent with right-sided pleural effusion (Figure 1). High-resolution computed tomography of the thorax demonstrated right-sided pleural effusion. A cavitory lesion measuring approximately 22.2×34.9×24.2 mm was identified in the right apicoposterior segment, with adjacent tractional bronchiectasis and air–fluid level. Additionally, multifocal patchy consolidations and

ground-glass opacities were noted on right lung, along with mediastinal lymphadenopathy (Figure 2).

Ultrasonography of abdomen and pelvis showed splenomegaly (14.3 cm) with a hypoechoic lesion suggestive of splenic abscess or cyst. Both kidneys demonstrated increased cortical echogenicity with preserved corticomedullary differentiation, along with bilateral hydronephrosis and a 10 mm calculus in the left kidney. The urinary bladder showed significant post-void residual urine (~510 ml), and the prostate was borderline enlarged (~25 cc).

Blood culture yielded growth of *Burkholderia pseudomallei*. Antibiotic susceptibility testing showed sensitivity to ceftazidime, carbapenems, doxycycline, minocycline, piperacillin-tazobactam and amoxicillin-clavulanic acid, while resistance was noted to cotrimoxazole, polymyxin-B and tetracycline.

The patient was managed with supplemental oxygen therapy, strict glycemic control and intravenous antibiotics tailored to culture sensitivity, including meropenem and doxycycline for 4 weeks. Further then doxycycline was given for long duration as maintenance therapy for 12 weeks. Supportive care and close monitoring were provided given the extent of systemic involvement. Patient was followed up in the outpatient department and his symptoms relieved over the duration of treatment. Repeat ultrasonography showed resolution of splenic lesions and prostatic enlargement. Chest Xray showed resolution of opacity in lung fields.

DISCUSSION

B. pseudomallei are small, gram-negative, oxidase-positive, motile, aerobic bacilli that reside in soil, water and plants in endemic regions.^{7,8} Transmission of *B. pseudomallei* occurs primarily through percutaneous inoculation and inhalation/aspiration. Ingestion is a common route of infection in grazing animals and a recent study suggested that for humans, ingestion of *B. pseudomallei* from unchlorinated domestic water supplies and other water sources such as rivers may be more common than previously thought.^{7,8} The environmental factors contributing to melioidosis include monsoons, skin abrasions, occupational hazards and physical injuries such as thorn pricks. Studies indicate that male agricultural workers are particularly vulnerable to melioidosis.⁹

Manifestations of melioidosis vary and can include localized to multifocal infection with or without septicemia. Though the most common presentation is pneumonia with symptoms similar to pulmonary tuberculosis it can also present as encephalomyelitis, septic arthritis, osteomyelitis and skin and visceral organ abscesses involving renal, splenic, prostatic and hepatic sites.¹⁰ The disease may also manifest as a cutaneous form, either due to a primary skin infection or dissemination from another infected organ. Skin lesions range from

papules and nodules to pustules and ulcers, resembling symptoms seen in other infectious diseases such as tuberculosis, plague, anthrax, cat scratch disease and sporotrichosis.¹¹ Familiarity with different presentations of this infection is essential for early diagnosis as delayed diagnosis contributes to increased mortality and morbidity. Melioidosis is associated with a range of mortality from 10-39%. For those with septic shock, it can rise up to 86%.¹²⁻¹⁴

B. pseudomallei exhibits resistance to penicillin's, aminoglycosides and relatively insensitive to macrolides and fluoroquinolones.^{14,15} Ceftazidime and carbapenems remain the drugs of choice during the intensive phase therapy. Use of meropenem especially in severe sepsis is advocated. Cotrimoxazole with or without doxycycline is used for the prolonged eradication phase. Doxycycline should not be used as monotherapy as drug resistance is expected.¹⁵ Adherence to therapy (24-week course of therapy) is the major factor that prevents relapse.

CONCLUSION

This case represents disseminated melioidosis in a poorly controlled diabetic patient, with involvement of the lungs, spleen, and genitourinary system. It underscores the importance of early microbiological diagnosis and prompt institution of targeted antimicrobial therapy to reduce morbidity and improve clinical outcomes. Modelled estimates of the global burden predict that melioidosis remains vastly under-reported and a call has been made for it to be recognized as a neglected tropical disease by the WHO.

Melioidosis should be suspected in the appropriate epidemiological setting with clinical presentation and necessary steps should be taken to confirm the diagnosis microbiologically. In the acute septicemic and subacute types, early aggressive therapy is essential to save life and antibiotics must be commenced empirically until microbiological diagnosis is established.

Funding: No funding sources

Conflict of interest: None declared

Ethical approval: Not required

REFERENCES

1. Cheng AC, Currie BJ. Melioidosis: epidemiology, pathophysiology and management. Clin Microbiol Rev. 2005;18(2):383-416.
2. Meumann EM, Limmathurotsakul D, Dunachie SJ, Wiersinga WJ, Currie BJ. *Burkholderia pseudomallei* and melioidosis. Nat Rev Microbiol. 2024;22(3):155-69.
3. Wiersinga WJ, Currie BJ, Peacock SJ. Melioidosis. N Engl J Med. 2012;367(11):1035-44.
4. Mohapatra PR, Mishra B. Burden of melioidosis in India and South Asia: challenges and ways forward. Lancet Reg Health Southeast Asia. 2022;2:100004.

5. West TE, Chierakul W, Chantratita N, Limmathurotsakul D, Wuthiekanun V, Emond MJ, et al. Toll-like receptor 4 region genetic variants are associated with susceptibility to melioidosis. *Genes Immun.* 2012;13(1):38-46.
6. Currie BJ, Ward L, Cheng AC. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20-year Darwin prospective study. *PLoS Negl Trop Dis.* 2010;4(11):e900.
7. Inglis TJJ, Garrow SC, Henderson M, Clair A, Sampson J, O'Reilly L, et al. The role of environmental reservoirs in the transmission of *Burkholderia pseudomallei*. *Microbes Infect.* 2000;2(8):941-6.
8. Limmathurotsakul D, Wuthiekanun V, Chierakul W, Amornchai P, Chaowagul W, Day NPJ, et al. Melioidosis caused by ingestion of contaminated water. *Emerg Infect Dis.* 2011;17(7):1237-9.
9. Kannan S, Singh S, Earny VA, Chowdhury S, Ashiq M, Eshwara VK, et al. Two decades of melioidosis in India: a comprehensive epidemiological review. *Pathogens.* 2025;14:379.
10. Dance DAB. Treatment and prophylaxis of melioidosis. *Int J Antimicrob Agents.* 2014;43(4):310-8.
11. Anjaneyan G, Duraisamy P, Kumar A, Manne S. Melioidosis presenting with groove sign. *J Dtsch Dermatol Ges.* 2023;21:182-4.
12. Currie BJ, Fisher DA, Howard DM, Burrow JN, Selvanayagam S, Snelling PL, et al. Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature. *Clin Infect Dis.* 2000;31(4):981-6.
13. Limmathurotsakul D, Golding N, Dance DAB, Messina JP, Pigott DM, Moyes CL, et al. Predicted global distribution of *Burkholderia pseudomallei* and burden of melioidosis. *Nat Microbiol.* 2016;1:15008.
14. Wiersinga WJ, Virk HS, Torres AG, Currie BJ, Peacock SJ, Dance DAB, et al. Melioidosis. *Nat Rev Dis Primers.* 2018;4:17107.
15. Savelkoel J, Dance DAB, Currie BJ, Limmathurotsakul D, Wiersinga WJ, Peacock SJ, et al. A call to action: time to recognise melioidosis as a neglected tropical disease. *Lancet Infect Dis.* 2022;22(6):e176-82.
16. Currie BJ. Melioidosis: evolving concepts in epidemiology, pathogenesis, and treatment. *Semin Respir Crit Care Med.* 2015;36(1):111-25.
17. Chakravorty A, Heath CH. Melioidosis: an updated review. *Aust J Gen Pract.* 2019;48(5):327-32.

Cite this article as: Dharme SS, Gaikwad PH, Jain PN, Kesare LV. A case of disseminated melioidosis: clinical insights and management. *Int J Res Med Sci* 2026;14:3078-81.